曲妥珠单抗、帕妥珠单抗联合多西他赛对晚期三阳性乳腺癌一线治疗的临床疗效

Clinical Efficacy of Trastuzumab, Pertuzumab and Docetaxel as First-Line Treatment for Metastatic Triple-Positive Breast Cancer

摘要: 目的：比较曲妥珠单抗、帕妥珠单抗联合多西他赛及曲妥珠单抗联合多西他赛、卡培他滨一线治疗晚期三阳性乳腺癌患者的临床疗效。方法：回顾性分析毓璜顶医院2019年1月至2020年6月收治的40例晚期三阳性乳腺癌患者临床病理资料。观察组采用曲妥珠单抗、帕妥珠单抗联合多西他赛的化疗方案，对照组采用曲妥珠单抗联合多西他赛、卡培他滨的化疗方案，两组患者均为20例。结果：至观察结束时，所有患者均完成化疗(4~6周期)，观察组治疗有效率为40%明显高于对照组有效率5%，差异有统计学意义(P < 0.05)。观察组、对照组无进展生存时间分别为18.20 ± 0.643个月、10.20 ± 0.835个月，差异有统计学意义(P < 0.05)。结论：在晚期三阳性乳腺癌的一线治疗中，曲妥珠单抗、帕妥珠单抗联合多西他赛相比于曲妥珠单抗联合多西他赛、卡培他滨能显著提高患者临床疗效及生活质量，但其不良反应发生率也更高。

Abstract: Objective: To compare the efficacy of first-line treatment with trastuzumab, pertuzumab plus docetaxel and trastuzumab plus docetaxel, capecitabine in patients with advanced tri-ple-positive breast cancer. Methods: A retrospective study was conducted on 40 patients with advanced triple positive breast cancer treated from January 2019 to June 2020 in the Yuhuang-ding hospital. The chemotherapy regimen of trastuzumab and pertuzumab plus docetaxel was used in the observation group, and the chemotherapy regimen of trastuzumab plus docetaxel and capecitabine was used in the control group (20 patients in both groups). Results: By the end of observation, all patients had completed chemotherapy (4~6 cycles), and the overall response rate (ORR) was 40% in the observation group, which was significantly higher than the ORR of 5% in the control group (P < 0.05). The progression free survival time was 18.20 ± 0.643 months in the observation group and 10.20 ± 0.835 months in the control group (P < 0.05). Conclusion: In the first-line treatment of metastatic triple-positive breast cancer, the combination of trastuzumab, pertuzumab, and docetaxel has significantly improved clinical outcomes and qual-ity of life compared with trastuzumab plus docetaxel and capecitabine but also has a higher in-cidence of adverse effects.